Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152864 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL6567834 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL29050069 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL627476 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL192488 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL20348248 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL1294140 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL192489 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL5955704 | 0.90 | ACE (0.51) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL18018402 | 0.90 | ACE (0.51) | CHRM2CHRM1CHRM3HSD17B10ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511368-A2 | CCR4 ANTAGONISTS | ChemoCentryx, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230382894-A1 | CCR4 ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023205618-A2 | CCR4 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20220380347-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-12-01 | — | — | US | disclosed |
| WO-2021212039-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-8637546-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV) | ABBVIE INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130059873-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC. | 2013-03-07 | — | — | US | disclosed |
| US-8119664-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
| EP-2102168-A1 | ACYLAMINOPYRAZOLES FOR TREATING CARDIOVASCULAR DISEASES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-23 | — | — | EP | disclosed |
| US-7262207-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1560811-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LAB (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007082666-A1 | ACYLAMINOIMIDAZOLES | BAYER HEALTHCARE AG (DE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007082666-A1 | ACYLAMINOIMIDAZOLES | BAYER HEALTHCARE AG (DE) | 2007-07-26 | — | — | WO | disclosed |
| US-7238724-B2 | Antidiabetic agents; hyperlipemic agents; obestity; immunomoderator; atherosclerosis | ABBOTT LABORATORIES (US) | 2007-07-03 | — | — | US | disclosed |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
| EP-1560811-A2 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | Abbott Laboratories (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
| WO-2004026822-A2 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382894-A1 | CCR4 ANTAGONISTS | CCR4, CCR1, CCR3 | CHRM2 106/4885CHRM1 107/4885CHRM3 72/4885 |
| US-20130059873-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | CHRM2 3368/4885CHRM1 3896/4885CHRM3 2553/4885 |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | CHRM2 3368/4885CHRM1 3896/4885CHRM3 2553/4885 |
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | CHRM2 3368/4885CHRM1 3896/4885CHRM3 2553/4885 |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | CHRM2 3398/4885CHRM1 3888/4885CHRM3 2553/4885 |
| US-20220380347-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | CHRM2 4884/4885CHRM1 4881/4885CHRM3 4686/4885 |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | CHRM2 3368/4885CHRM1 3896/4885CHRM3 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.